Track topics on Twitter Track topics that are important to you
AbbVie has exercised its exclusive license option to develop and commercialize argenx’s preclinical cancer immunotherapy ARGX-115, argenx said today, making the Belgian biotech eligible for up to $625 million in milestone payments, plus royalties. AbbVie’s decision comes two months after the company paid argenx $10 million following achievement of a second unspecified preclinical milestone in the companies’ two-year-old collaboration. AbbVie paid argenx $10 million for achieving the first preclinical milestone in April 2017, and $40 million upfront for the exclusive option to license ARGX-115 when the companies launched their collaboration in April 2016 . Under the collaboration, AbbVie also agreed to pay argenx up to $625 million tied to achieving development, regulatory and commercial milestones, plus tiered royalties on ARGX-115-based product sales. argenx also has the right to co-promote ARGX-115-based products in the EU and Swiss Economic Area. “Our collaboration with argenx over the past ...
Original Article: AbbVie Exercises Option to Develop argenx Cancer Immunotherapy ARGX-115NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...